HDinHD: Open Source Science for the HD Research Community
The goal of HDinHD is to foster and support a collaborative community united in its drive to accelerate the development of therapeutics that will delay the onset and/or ameliorate the effects of Huntington’s disease. HDinHD seeks to achieve this through:
- Sharing HD-related primary scientific data
- Sharing analyses and computational models built from HD-related scientific data
- Providing browsing and data interrogation tools over both primary and analyzed data that facilitate data exploration and hypothesis generation
- Building a forum for HD researchers to highlight their data, tools, know-how and insight to the community
The HDinHD website – founded as a partnership between CHDI and the Coppola Lab at UCLA – is currently a joint development effort by CHDI, Bridlewood Consulting and Rancho BioSciences. As you will see when you Register for access, HDinHD highlights data and tools provided by the broader community. If you are interested in Contributing Data to HDinHD, suggest links to other HD-related scientific data or websites, or would otherwise like to provide Feedback to us, we encourage you to do so. HDinHD is for the community; please help us tailor and grow HDinHD in a direction that can make a difference to your research, and ultimately, to improve the lives of HD families.
Want to learn more about HDinHD?
| Watch a detailed video overview of HDinHD presented at the 16th Annual HD Therapeutics Conference (April 2021). The video outlines data resources and tools within HDinHD and provides a detailed demonstration of the new HD Explorer tool. |
Read the following publication introducing HDinHD: HDinHD: A Rich Data Portal for Huntington’s Disease Research, J Huntingtons Dis., 10, 405-412
Latest news and publications from around the HD Ecosystem
HDBuzz
- FDA sets May 2027 decision date on AMT-130 gene therapy for HD
- October 2026: This Month in Huntington’s Disease Research
- Turning down huntingtin: Alnylam’s brezosiran shows promising early result
- Blurred Lines: When Similar Symptoms Can Mean Different Things
- Picking MSH3’s Pocket: New Insights into CAG Repeat Expansion
Literature
- Rhes as a Potential Modulator of PINK1/Parkin-Dependent Mitophagy in Huntington's Disease
- The postsynaptic scaffolding protein SAPAP3 shapes mitochondrial activity: the case of Huntington's disease
- Bioinformatics Analysis to Reveal Potential Targets of Huntington's Disease
- Computational modeling and preclinical evaluation support targeting somatic instability for Huntington's disease treatment
- Quantifying multidisciplinary collaboration in Huntington's disease before and after service redesign: a social network analysis
News
- QURE SWOT Analysis: Financial Struggles Amid Promising Gene Ther - GuruFocus
- Key facts: AMT-130 Priority Review; 48-Month Data; Q3 Revenue +40% - TradingView
- Design Therapeutics 3Q 2026: Net loss $20.3M, diluted EPS $(0.32) — 10-Q Summary
- Design Therapeutics Reports Q3 2026 Results, $208.6 Million in Cash and Securities
- With technical barriers to human embryo editing falling, ethical concerns escalate




